FDA approves Novartis osteoarthritis treatment

10/23/2007 | Forbes · Reuters

Novartis AG's topical treatment for osteoarthritis, called Voltaren Gel, was awarded FDA approval, the company announced Monday. Clinical trials showed that the nonsteroidal anti-inflammatory drug can reduce pain in both the knees and joints of the hands by 51% with minimal side effects.

View Full Article in:

Forbes · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC